MDM2 is primarily controlled by wtp53, and its expression level is diminished in cancer cells harboring p53 mutations, which may contribute to reduce the turnover of EZH2 and result in the accumulation of EZH2 in mutp53-carrying cells [56]. Here, TP53 is linked to cancer.